Michael Bauer Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Assitstant Professor

University of Arkansas for Medical Sciences

faculty

24 h-index 396 pubs 3,244 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Michael Bauer's research group at the University of Arkansas for Medical Sciences focuses on understanding the molecular and genomic underpinnings of multiple myeloma. His work investigates the evolutionary trajectories of the disease, from its precursor stages to advanced, refractory states. This includes characterizing the role of the immune microenvironment at a single-cell level and identifying how structural variants and chromothripsis contribute to the genomic landscape and clinical outcomes of multiple myeloma.

Bauer's research also extends to identifying molecular signatures that predict treatment-related toxicities. He has investigated genome-wide DNA methylation signatures associated with early, asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients. His work has also explored environmental factors, such as low-level heavy metal exposure, and their association with health conditions like obesity in postmenopausal women.

With a substantial publication record (396 total publications) and a citation count of 3,244, Bauer is recognized as a highly cited researcher. He has established collaborations with several colleagues at the University of Arkansas for Medical Sciences, including Cody Ashby, Christopher P. Wardell, Sharmilan Thanendrarajan, and Maurizio Zangari, with whom he shares multiple publications.

Metrics

h-index: 24
Publications: 396
Citations: 3,244

Selected Publications

How Does Age at Diagnosis Influence Multiple Myeloma Survival? Empirical Evidence (2025) DOI
Start Time End Time Integration (STETI): Method for Including Recent Data to Analyze Trends in Kidney Cancer Survival (2025) DOI
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
RNA sequencing of formalin fixed paraffin-embedded heart tissue provides transcriptomic information about chemotherapy-induced cardiotoxicity (2024) DOI
Increased Utilization of Low-Dose CT for Lung Cancer Screening at an Arkansas Community Oncology Clinic (2023) DOI
1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma (2023) DOI
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023) DOI
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression (2023) DOI
Abstract B015: Racial differences in epigenetic aging and its impact on expression of T-cell inhibitory receptors (2023) DOI
Identification of novel long noncoding RNA with distinct expression patterns in different subtypes of multiple myeloma (2022) DOI
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level (2022) DOI
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022) DOI
Abstract 2242: Impact of low-dose computed tomography screening for lung cancer at a community oncology clinic on stage of lung cancer diagnosis in the catchment area (2022) DOI
Structural variants shape the genomic landscape and clinical outcome of multiple myeloma (2022) DOI